Edition:
India

Aurinia Pharmaceuticals Inc (AUP.TO)

AUP.TO on Toronto Stock Exchange

24.04CAD
25 Feb 2020
Change (% chg)

-- (--)
Prev Close
$24.04
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
171,943
52-wk High
$28.59
52-wk Low
$4.70

Latest Key Developments (Source: Significant Developments)

Aurinia Prices $166.7 Mln Public Offering Of Common Shares At $15 Per Share
Tuesday, 10 Dec 2019 

Dec 9 (Reuters) - Aurinia Pharmaceuticals Inc ::AURINIA PRICES US$166.7 MILLION PUBLIC OFFERING OF COMMON SHARES.SHARES ARE BEING SOLD AT A PUBLIC OFFERING PRICE OF US$15.00 PER SHARE.  Full Article

Aurinia Pharmaceuticals Announces Public Offering Of Common Shares
Monday, 9 Dec 2019 

Dec 9 (Reuters) - Aurinia Pharmaceuticals Inc ::AURINIA ANNOUNCES PUBLIC OFFERING OF COMMON SHARES.AURINIA PHARMACEUTICALS INC - ANNOUNCED THAT IT HAS COMMENCED A REGISTERED UNDERWRITTEN PUBLIC OFFERING OF $150 MILLION OF ITS COMMON SHARES.AURINIA PHARMACEUTICALS INC - INTENDS TO USE NET PROCEEDS OF OFFERING FOR PRE-COMMERCIALIZATION AND LAUNCH ACTIVITIES.  Full Article

Aurinia Announces Positive Aurora Phase 3 Trial Results Demonstrating Voclosporin Superiority Over Standard Of Care In Lupus Nephritis
Thursday, 5 Dec 2019 

Dec 4 (Reuters) - Aurinia Pharmaceuticals Inc ::AURINIA ANNOUNCES POSITIVE AURORA PHASE 3 TRIAL RESULTS DEMONSTRATING VOCLOSPORIN SUPERIORITY OVER STANDARD OF CARE IN LUPUS NEPHRITIS.AURINIA PHARMACEUTICALS INC - STATISTICALLY SIGNIFICANT RESULTS DEMONSTRATED IN ALL PRE-SPECIFIED HIERARCHICAL SECONDARY ENDPOINTS.AURINIA PHARMACEUTICALS INC - AURINIA PLANS TO FILE AN NDA SUBMISSION TO FDA DURING FIRST HALF OF 2020.AURINIA PHARMACEUTICALS - VOCLOSPORIN ACHIEVED STATISTICALLY SUPERIOR RENAL RESPONSE RATE AND COMPARABLE SAFETY PROFILE VERSUS STANDARD OF CARE.AURINIA PHARMACEUTICALS INC - VOCLOSPORIN WAS WELL TOLERATED WITH NO UNEXPECTED SAFETY SIGNALS.  Full Article

Aurinia Reports Last Patient Study Visit In Aurora Phase 3 Lupus Nephritis Study And Provides Update On ATM Facility
Wednesday, 16 Oct 2019 

Oct 16 (Reuters) - Aurinia Pharmaceuticals Inc ::AURINIA REPORTS LAST PATIENT STUDY VISIT IN AURORA PHASE 3 LUPUS NEPHRITIS STUDY AND PROVIDES UPDATE ON ATM FACILITY.AURINIA PHARMACEUTICALS - AURORA PHASE 3 RESULTS WITH VOCLOSPORIN FOR TREATMENT OF LUPUS NEPHRITIS REMAIN ON TRACK TO BE REPORTED BY END OF Q4 2019.AURINIA PHARMACEUTICALS INC - CO DOES NOT INTEND TO CONDUCT FURTHER SALES PURSUANT TO ATM AT THIS TIME.  Full Article

Aurinia Reports Q2 2019 Results
Wednesday, 7 Aug 2019 

Aug 6 (Reuters) - Aurinia Pharmaceuticals Inc ::AURINIA REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS.AURINIA PHARMACEUTICALS INC - INITIATING AUDREY™ PHASE 2/3 CLINICAL STUDY FOR VOS IN DRY EYE SYNDROME.AURINIA PHARMACEUTICALS INC - FULLY-ENROLLED AURORA PHASE 3 TRIAL IN LUPUS NEPHRITIS CONTINUES ON TRACK WITH RESULTS ANTICIPATED IN LATE 2019.AURINIA PHARMACEUTICALS INC QTRLY LOSS PER SHARE $0.17.  Full Article

Aurinia Announces Voclosporin Ophthalmic Solution Demonstrates Superior Efficacy In A Phase 2 Head-To-Head Study
Tuesday, 22 Jan 2019 

Jan 22 (Reuters) - Aurinia Pharmaceuticals Inc ::AURINIA ANNOUNCES VOCLOSPORIN OPHTHALMIC SOLUTION DEMONSTRATES STATISTICALLY SUPERIOR EFFICACY VERSUS RESTASIS® IN A PHASE 2 HEAD-TO-HEAD STUDY FOR THE TREATMENT OF DRY EYE SYNDROME.AURINIA PHARMACEUTICALS INC - PRIMARY ENDPOINT OF DROP DISCOMFORT AT 1-MINUTE ON DAY 1 SHOWED NO STATISTICAL DIFFERENCE BETWEEN VOS AND RESTASIS.AURINIA PHARMACEUTICALS INC - NO SERIOUS ADVERSE EVENTS WERE REPORTED IN STUDY, AND THERE WERE NO UNEXPECTED SAFETY SIGNALS..  Full Article

Aurinia Pharmaceuticals Reports Qtrly Loss Per Share ‍of $0.04​
Friday, 16 Mar 2018 

March 15 (Reuters) - Aurinia Pharmaceuticals Inc ::AURINIA REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS.AURINIA PHARMACEUTICALS INC QTRLY LOSS PER SHARE ‍$0.04​.AURINIA PHARMACEUTICALS INC - ‍TRIALS IN FSGS AND DRY EYE TO BEGIN IN Q2 2018​.  Full Article

BRIEF-Aurinia Appoints Max Colao As Chief Commercial Officer And Expands U.S. Commercial Leadership Team

* AURINIA APPOINTS MAX COLAO AS CHIEF COMMERCIAL OFFICER AND EXPANDS U.S. COMMERCIAL LEADERSHIP TEAM Source text for Eikon: Further company coverage: